Industry Outlook: Healthcare & Life Sciences — Week of July 20, 2026

Market Outlook

• AI moves deeper into utilization management. Democratic lawmakers are pushing resolutions to halt the WISeR model that brings AI-driven prior authorization into traditional Medicare, while healthcare groups are backing a bipartisan Medicare Advantage prior auth reform bill. At the same time, MedCity highlights a "bot vs bot" dynamic where provider and payer automation are escalating administrative costs rather than reducing them. CTOs should expect growing regulatory scrutiny of AI in coverage decisions and higher expectations for auditability and fairness in any automation that affects payment or access to care.
• RPM business models hit by CMS crackdown. A draft Medicare physician fee schedule includes major changes to remote patient monitoring reimbursement, and CMS is separately trying to ban third-party RPM vendors from billing under physicians. These moves directly challenge many RPM platforms' economics and will favor integrated, clinically supervised models over outsourced, call-center style services. Vendors and providers that cannot prove direct clinical integration and quality impact will struggle to sustain RPM programs at scale.
• Virtual and data-rich care models keep scaling. West Tennessee Healthcare is expanding its systemwide eICU program using Philips eCareManager integrated with hellocare.ai, and Catholic Health is rolling out more than 1,300 new technologies across 40 sites with added digital tools and operational support. Behavioral health group Thriveworks is offering referring providers dashboards that expose connection-to-care status, clinical progress, and medication changes. Health systems are standardizing on integrated virtual care stacks and closing feedback loops with richer longitudinal data, which raises the bar for interoperability and analytics capabilities.

Discussion: CTOs should stress test AI-driven utilization management and RPM offerings against likely CMS and congressional actions, and prioritize platforms that integrate tightly with clinical workflows and EHR data rather than standalone services.

Headwinds

• Regulatory backlash to AI prior authorization. UnitedHealthcare is publicly criticizing the No Surprises Act dispute resolution process, while lawmakers target the WISeR AI prior auth model and advance separate MA prior auth reforms. Public and political tolerance for opaque AI in coverage decisions is dropping, especially where denials, delays, or surprise bills are involved. Any AI that touches prior auth, utilization review, or payment integrity will face higher evidentiary standards, explainability requirements, and potential legal exposure.
• CMS pressure on third-party RPM and telehealth. Proposed Medicare policy changes would curtail billing for third-party RPM providers and tighten definitions of eligible services, which could wipe out volume for vendors that depend on loosely supervised monitoring. Experts are warning of significant disruption to providers' RPM programs, especially those built around outsourced staffing and device logistics. Telemedicine and digital therapeutic models that rely heavily on RPM revenue need contingency plans and clearer proof of clinical value.
• Automation arms race inflates payer-provider costs. MedCity reports a "bot vs bot" dynamic in which providers deploy AI to optimize coding and claims, while payers counter with AI for denials and audits, driving up friction and administrative cost. Without shared standards and transparency, both sides risk algorithmic escalation, more disputes, and degraded clinician and patient experience. CIOs and CTOs that treat AI as a zero-sum weapon in revenue cycle rather than a shared infrastructure for data quality and clinical decision support will see rising integration and compliance costs.

Discussion: Defensively, CTOs should catalog where AI influences financial decisions, strengthen documentation and model governance, and design RPM and telehealth architectures that can survive less favorable reimbursement and stricter supervision rules.

Tailwinds

• AI-ready public health and analytics demand. MedCity highlights growing interest in AI-ready public health data systems for faster, safer decision making, reflecting lessons from COVID and recent outbreaks. Health agencies and large providers are looking for platforms that combine FHIR-native data models, high-quality reference terminologies, and built-in support for surveillance and forecasting. Vendors that can bridge EHR, claims, and public health data with strong privacy controls will find receptive buyers among health systems and governments.
• Capital flows to data-driven care and diagnostics. Neko Health raised 700 million dollars for its US expansion of tech-heavy preventive diagnostics, and Juno Bio secured funding for vaginal microbiome testing. These deals show investor conviction in data-rich, longitudinal care models that depend on solid interoperability, analytics, and patient engagement layers. The MedCity piece on GLP-1s also points to a need for better real-world outcome measurement, opening space for digital biomarkers, registries, and AI-supported risk models.
• Clinical AI focus shifts to outcomes and burnout. MedCity commentary argues for moving from "acceptable" to optimal outcomes with clinical AI, and another piece calls for specialty-specific approaches to burnout measurement and intervention. There is growing appetite for AI that directly affects quality metrics, clinician workload, and patient outcomes rather than generic productivity tools. CTOs who can connect AI projects to measurable improvements in specialty workflows and outcomes will gain budget and clinician support.

Discussion: To capitalize, prioritize platforms that treat high-quality, standardized data as a product, and invest in clinical AI pilots that tie directly to specialty outcomes and measurable reductions in burnout or avoidable utilization.

Tech Implications

• Interoperable virtual care stacks become table stakes. The Philips eICU expansion with hellocare.ai and Catholic Health's 1,300-tech rollout show health systems consolidating around integrated virtual care and monitoring stacks. Thriveworks' referral dashboards hint at expectations that behavioral health and other partners expose structured status and outcome data back to referring providers. Architectures that do not use FHIR, HL7, and standard vocabularies to push and pull longitudinal data into EHRs will struggle to win enterprise deals.
• AI governance must extend beyond clinical decision support. AI in prior authorization and revenue cycle is drawing as much scrutiny as clinical AI, yet many organizations have governance focused only on diagnostic or therapeutic models. The "bot vs bot" pattern and WISeR backlash show that financial and operational AI can trigger reputational, legal, and regulatory risk. Enterprise AI governance needs a single inventory of models, clear ownership, monitoring of bias and error rates, and traceability for both clinical and administrative use cases.
• Data models must support value-based and psychedelic care. Eli Lilly's 2.8 billion dollar AtaiBeckley acquisition signals that psychedelic-assisted therapies are moving toward mainstream pipelines, which will require new data capture for session context, integration of psychotherapy notes, and safety monitoring. At the same time, GLP-1 commentary highlights a shift to outcomes that matter to patients, such as function and quality of life, not just weight. EHR and data warehouse schemas will need to handle richer patient-reported outcomes, longitudinal behavioral data, and new therapy modalities to support value-based contracts and FDA post-market expectations.

Discussion: Engineering teams should double down on FHIR-first designs, event-driven data pipelines, and a unified AI registry, and begin extending data models to cover emerging therapies and richer patient-reported and behavioral data.

CTO Action Items

Start the week by reviewing your portfolio of AI systems that influence coverage, payment, or utilization management, and ensure each has clear documentation, monitoring, and a defensible audit trail ahead of likely CMS and congressional scrutiny. Ask your RPM and telemedicine leads for a scenario plan that assumes tighter Medicare rules and reduced third-party billing, then identify which platforms can be reconfigured for more direct clinician supervision and outcome tracking. On the architecture side, push for a concrete roadmap to make virtual care, behavioral health, and external partners exchange data via FHIR and standard vocabularies, including referral status and outcomes. Finally, earmark capacity for one or two high-visibility clinical AI pilots that target specialty-specific burnout or outcome gaps, and insist on rigorous measurement so you can defend these investments to boards and regulators.